June 2010
Ocular Surgery News;6/25/2010, Vol. 28 Issue 12, p54
Academic Journal
This section offers news briefs related to ocular surgery. The VisionLock patient care plan for laser-assisted in situ keratomileusis (LASIK) and premium intraocular lens (IOL) surgery has been available in Florida by Patient Confidence Corp. of America. A gatifloxacin ophthalmic solution 0.5 percent from Allergan has been approved by the U.S. Food and Drug Administration (FDA) for treating bacterial conjunctivitis. The marketing of Bausch + Lomb's Crystalens AO in quarter diopter steps has been approved by the FDA.


Related Articles

  • Early Users Share the enVista Experience. Stephenson, Michelle // Review of Ophthalmology;Jan2013, Vol. 20 Issue 1, p38 

    The article focuses on enVista, a hydrophobic acrylic intraocular lens (ILO) launched by Bausch and Lomb Inc. It is the only lens which has been approved by the U.S. Food and Drug Administration (FDA) and has been labeled as glistening free. Physician Peter Heimer from the Vision Eye Institute...

  • Refractive and anatomic accuracy vital with accommodating IOLs. Devgan, Uday // Ocular Surgery News;9/25/2008, Vol. 26 Issue 18, p69 

    The article offers information on accommodating intraocular lens (IOL) and the need of surgeons to address the corneal astigmatism by adjusting incisional methods. It states that the only accommodating IOL approved by the U.S. Food and Drug Administration (FDA) is the Crystalens from Bausch &...

  • Approval Expands Crystalens Options.  // Review of Ophthalmology;Aug2009, Vol. 16 Issue 8, p13 

    The article reports that Bausch & Lomb Inc. has received approval from the U.S. Food and Drug Administration (FDA) to market the Crystalens high definition (HD) accommodating intraocular lens. The Quarter diopters feature Crystalens HD for the models of HD00 and HD520 intraocular lens. Moreover,...

  • B&L accommodating IOL, eyetracker available.  // Ophthalmology Times;10/1/2008, Vol. 33 Issue 19, p6 

    The article reports on the launching of the fourth generation of intraocular lens (IOL) by Bausch & Lomb in Europe in July 2008. The lens, which has been approved by the U.S. Food and Drug Administration (FDA), provides an enhanced depth of focus designed to improve near vision without...

  • B&L to begin marketing new Crystalens HD in U.S.  // Medical Device Daily;7/1/2008, Vol. 12 Issue 126, p9 

    The article reports on the announcement from eye health company Bausch & Lomb Surgical of Aliso Viejo, California that it has received approval from the U.S. Food and Drug Administration (FDA) to market the Crystalens HD accommodating intraocular lens (IOL) in the country. It is said that the...

  • Regarding the paper: Hydroview lens implant calcification—186 exchanges at a district general hospital, by P Syam et al. Tetz, M.; Werner, L. // Eye;Mar2008, Vol. 22 Issue 3, p323 

    The author reflects on the study which discusses an experience at a district hospital with 174 consecutive intraocular lenses (IOL) exchanges because of calcification of the Hydroview lens from Bausch & Lamb Inc. The author mentions the first calcified exchange in 2002, with the onset of...

  • Wavefront-guided LASIK tackles mixed astigmatism. Thilesen, Trond // Ophthalmology Times;4/1/2007, Vol. 32 Issue 7, p49 

    The article reports on the result of the study which examines the efficacy of a customized laser in situ keratomileusis (LASIK) procedure with Zyoptix from Bausch & Lomb Inc. for the treatment of astigmatism in Larvik, Norway. Forty-three eyes with mixed astigmatism were the subjects of the...

  • Etiology of postop astigmatism sought after wavefront-guided LASIK. Guttman, Cheryl // Ophthalmology Times;2/1/2006, Vol. 31 Issue 3, p26 

    The article reports on discussions by Scott M. MacRae on the risk factors for postoperative astigmatism after wavefront-guided LASIK using the Zyoptix platform developed by Bausch & Lomb. The risk factors are preoperative coma and the difference between the preoperative manifest and wavefront...

  • FDA Clearance for B+L Stellaris PC System.  // Review of Ophthalmology;May2014, Vol. 21 Issue 5, p94 

    The article evaluates the Stellaris PC (Procedural Choice) Vision Enhancement System, an ophthalmic surgical system, by Bausch and Lomb Inc. which has received clearance from the U.S. Food and Drug Administration (FDA) for the integrated 532-nm (nanometer) laser and software, as of May 2014.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics